Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

ClinicalTrials.gov ID: NCT02963935

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02963935. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted in the United States of America (USA). The purpose of the trial is to investigate the effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist setting (IBT-CMS: Intensive Behaviour Therapy for obesity in a primary care setting according to Centers for Medicare \& Medicaid Services (CMS) visit schedule).

Study identification

NCT ID: NCT02963935
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Novo Nordisk A/S; Industry
Enrollment: 282 participants

Conditions and interventions

Conditions

Interventions

liraglutide Drug
placebo Drug
CMS Intensive Behavior Therapy Behavioral

Drug · Behavioral

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 6, 2017 (Actual)
Primary completion: May 23, 2018 (Actual)
Completion: Jun 19, 2018 (Actual)
Last update posted: Mar 11, 2020

2017 – 2018

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
Novo Nordisk Investigational Site	Jacksonville	Florida	32205	—
Novo Nordisk Investigational Site	Plantation	Florida	33324	—
Novo Nordisk Investigational Site	Chicago	Illinois	60607	—
Novo Nordisk Investigational Site	Greensboro	North Carolina	27408	—
Novo Nordisk Investigational Site	Salisbury	North Carolina	28144	—
Novo Nordisk Investigational Site	Wadsworth	Ohio	44281	—
Novo Nordisk Investigational Site	Philadelphia	Pennsylvania	19104-3317	—
Novo Nordisk Investigational Site	Charleston	South Carolina	29425	—
Novo Nordisk Investigational Site	Dallas	Texas	75251	—
Novo Nordisk Investigational Site	Arlington	Virginia	22206	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02963935, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 11, 2020 · Synced Nov 12, 2026